<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2908">
  <stage>Registered</stage>
  <submitdate>9/09/2010</submitdate>
  <approvaldate>9/09/2010</approvaldate>
  <nctid>NCT01199588</nctid>
  <trial_identification>
    <studytitle>A Study to Investigate the Efficacy, Safety and Tolerability of Nexagon® as a Topical Treatment for Subjects With Venous Leg Ulcers</studytitle>
    <scientifictitle>A Randomized, Parallel Group, Dose-Ranging, Controlled, Multi-Center Study to Assess the Efficacy and Safety of Nexagon® in the Treatment of Subjects With a Venous Leg Ulcer</scientifictitle>
    <utrn />
    <trialacronym>NOVEL2</trialacronym>
    <secondaryid>NEX-ULC-007</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Venous Leg Ulcers</healthcondition>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Skin</conditioncode1>
      <conditioncode2>Other skin conditions</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Diseases of the vasculature and circulation including the lymphatic system</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Nexagon® Low Dose
Treatment: drugs - Nexagon® High Dose
Treatment: drugs - Nexagon® Vehicle

Experimental: Nexagon® High Dose - Weekly applications of Nexagon® high dose in addition to compression dressings.

Placebo Comparator: Nexagon® Vehicle - Weekly applications of Nexagon® Vehicle in addition to compression dressings.

No Intervention: No Investigational Product - Weekly application of compression dressings.

Experimental: Nexagon® Low Dose - Weekly applications of Nexagon® low dose in addition to compression dressings.


Treatment: drugs: Nexagon® Low Dose
Weekly, topical application of Nexagon® low dose used with compression dressings.

Treatment: drugs: Nexagon® High Dose
Weekly, topical application of Nexagon® high dose used with compression dressings.

Treatment: drugs: Nexagon® Vehicle
Weekly, topical application of Nexagon® Vehicle used with compression dressings.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Surface area reduction</outcome>
      <timepoint>10 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence of complete closure</outcome>
      <timepoint>10 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to complete closure</outcome>
      <timepoint>10 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence of ulcer recurrence</outcome>
      <timepoint>12 weeks post closure</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pain</outcome>
      <timepoint>10 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence of adverse events</outcome>
      <timepoint>10 weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Diagnosis of venous leg ulceration supported by venous duplex ultrasonography
             demonstrating venous reflux &gt; 0.5 seconds

          2. Ankle brachial index of &gt; 0.80

          3. Venous Leg Ulcer (VLU) area greater than 2 cm2 and less than 20 cm2

          4. Compliant with and able to tolerate high compression bandaging

          5. VLU present for &gt; 30 days prior to study entry

          6. VLU is full thickness

          7. The subject is willing and able to give informed consent</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Decrease or increase in the ulcer surface area by more than 40% during the 14 day
             run-in period

          2. More than 75% of the VLU is on or below the malleolus

          3. Presence of a non-study ulcer within 1.5 cm of the VLU

          4. A VLU which shows signs of clinical infection or has cellulitis

          5. The VLU wound bed has exposed bone, tendon or fascia

          6. BMI &gt; 45.0 kg/m2

          7. Subject is not ambulatory

          8. Subjects who have a past or present disease that, which as judged by the Investigator,
             may affect the safety of the subject or the outcome of the study

          9. Cancerous cells in the VLU

         10. HbA1c &gt;10%

         11. Blood biochemistry &gt;3x upper limit of normal

         12. Heart failure NYHA class III or IV

         13. Subjects on renal replacement therapy

         14. Immunocompromized subjects</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/05/2011</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>300</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/03/2013</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,VIC</recruitmentstate>
    <hospital>South Sydney Vascular Centre - Sydney</hospital>
    <hospital>Heidelberg Repatriation Hospital - Melbourne</hospital>
    <postcode>2228 - Sydney</postcode>
    <postcode> - Melbourne</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arizona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Nevada</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Jersey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oklahoma</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Utah</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Otago</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Gauteng</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Bloemfontein</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Cape Town</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Durban</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Johannesburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Port Elizabeth</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>CoDa Therapeutics Inc.</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study is for subjects with a venous leg ulcer. The study is being done to determine if
      NEXAGON plus compression bandaging is more effective that placebo plus compression bandaging.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01199588</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Tom Serena, MD</name>
      <address>Penn North Centers For Advanced Wound Care, PA, USA</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>